Health Ever Bio-Tech Co., Ltd.
Quick facts
Phase 3 pipeline
- MCS · Cardiovascular
MCS is a small molecule that targets the molecular target. - MCS-2 · Diabetes
MCS-2 is a small molecule that targets the SGLT2 receptor.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Health Ever Bio-Tech Co., Ltd. portfolio CI brief
- Health Ever Bio-Tech Co., Ltd. pipeline updates RSS
Frequently asked questions about Health Ever Bio-Tech Co., Ltd.
What is Health Ever Bio-Tech Co., Ltd.'s pipeline?
Health Ever Bio-Tech Co., Ltd. has 2 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include MCS, MCS-2.
Related
- Sector hub: All tracked pharma companies